These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23289459)

  • 1. Evaluation of inhaler technique and patient satisfaction with fixed-combination budesonide/formoterol dry-powder inhaler in chronic obstructive pulmonary disease (COPD): data on real-life clinical practice in Turkey.
    Öztürk C; Kaya A; Bilgin C; Yücesoy L; İkidağ B; Demirel M; Başlılar Ş; Şaylan B; Senol T; Ağanoğlu S; Can G; Doğrul MI; Çam M; Erdoğan N; Batum Ö; Turan MO; Demir C; Torun Ş; Cirit M; Turan M; Keleşoğlu A; Yaşar S; Uzunay Ö; Melek K; Altıparmak O
    Tuberk Toraks; 2012; 60(4):301-13. PubMed ID: 23289459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
    Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
    Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair
    Yildiz P; Bayraktaroglu M; Gorgun D; Yuksel K
    Clin Drug Investig; 2019 Oct; 39(10):991-1001. PubMed ID: 31332649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide + formoterol delivered via Spiromax
    Lewis A; Torvinen S; Dekhuijzen PNR; Chrystyn H; Melani A; Zöllner Y; Kolbe K; Watson AT; Blackney M; Plich A
    Respir Med; 2017 Aug; 129():179-188. PubMed ID: 28732829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study.
    Price DB; Thomas V; Richard Dekhuijzen PN; Bosnic-Anticevich S; Roche N; Lavorini F; Raju P; Freeman D; Nicholls C; Small IR; Sims E; Safioti G; Canvin J; Chrystyn H
    BMC Pulm Med; 2018 Jun; 18(1):107. PubMed ID: 29954359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
    Cazzola M; Ora J; Di Paolo A; Puxeddu E; Calzetta L; Rogliani P
    Pulm Pharmacol Ther; 2016 Aug; 39():48-53. PubMed ID: 27344046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).
    Malmberg LP; Everard ML; Haikarainen J; Lähelmä S
    J Aerosol Med Pulm Drug Deliv; 2014 Oct; 27(5):329-40. PubMed ID: 24978441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries.
    Lewis A; Torvinen S; Dekhuijzen PN; Chrystyn H; Watson AT; Blackney M; Plich A
    BMC Health Serv Res; 2016 Jul; 16():251. PubMed ID: 27406133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol Turbuhaler® in adults and adolescents with persistent asthma.
    Virchow JC; Rodriguez-Roisin R; Papi A; Shah TP; Gopalan G
    BMC Pulm Med; 2016 Mar; 16():42. PubMed ID: 26987997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.
    Voorham J; Roche N; Benhaddi H; van der Tol M; Carter V; van Boven JFM; Bjermer L; Miravitlles M; Price DB
    BMJ Open; 2018 Oct; 8(10):e022051. PubMed ID: 30368448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide/formoterol combination in COPD: a US perspective.
    Sharafkhaneh A; Mattewal AS; Abraham VM; Dronavalli G; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2010 Oct; 5():357-66. PubMed ID: 21037960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD.
    Gálffy G; Mezei G; Németh G; Tamási L; Müller V; Selroos O; Orosz M
    Drugs R D; 2013 Sep; 13(3):215-22. PubMed ID: 24043456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
    Löfdahl CG; Ericsson A; Svensson K; Andreasson E
    Pharmacoeconomics; 2005; 23(4):365-75. PubMed ID: 15853436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease.
    Centanni S; Di Marco F
    Expert Opin Pharmacother; 2005 Nov; 6(14):2525-34. PubMed ID: 16259583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADRB2 polymorphisms and budesonide/formoterol responses in COPD.
    Bleecker ER; Meyers DA; Bailey WC; Sims AM; Bujac SR; Goldman M; Martin UJ
    Chest; 2012 Aug; 142(2):320-328. PubMed ID: 22383665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study.
    Zervas E; Samitas K; Gaga M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1845-55. PubMed ID: 27540287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.